8-K: KORU Medical Hits Record Revenue, Boosts 2025 Outlook

KORU Medical Systems reported record Q2 2025 net revenues of $10.2 million, a 21% increase year-over-year, and raised its full-year 2025 revenue guidance.

Summary

• Net revenues for Q2 2025 reached $10.2 million, marking a 20.9% increase over the prior year period and the first time surpassing $10 million.
• Core business net revenues (Domestic and International) grew by 19% to $9.3 million.
• Pharma Services and Clinical Trials (PST) net revenues increased by 42% to $0.9 million.
• Gross profit rose by 18% to $6.5 million, though gross margin slightly decreased to 63.5% from 65.0% in the prior year.
• Net loss significantly decreased to $0.2 million in Q2 2025, compared to a $0.98 million net loss in the prior year period.
• Adjusted EBITDA for Q2 2025 was positive at $0.3 million, or $0.01 per diluted share, a substantial improvement from ($0.4) million, or ($0.01) per diluted share, in the prior year.
• The company raised its full-year 2025 net revenue guidance to a range of $39.5 million to $40.5 million, representing 18% to 20% growth, up from the previous range of $38.5 million to $39.5 million.
• Full-year gross margin guidance was reiterated at 61% to 63%, and positive cash flow from operations for full year 2025 was reaffirmed, with an expected ending cash balance greater than $8.1 million.
• Adam Kalbermatten was appointed as Chief Commercial Officer.
• The Freedom Infusion System received an expanded indication for use with Empaveli for C3G and Primary IC-MPGN treatment.
• A 510(k) clearance submission was made to the FDA for a commercialized rare disease biologic drug with the Freedom Infusion System.

Sentiment

Score: 8

Explanation: The company reported strong financial results, including record revenue and positive adjusted EBITDA, along with raised full-year guidance. Strategic initiatives like new management, expanded indications, and FDA submissions indicate positive momentum and future growth potential, despite a slight dip in gross margin and continued cash usage.

Positives

• Achieved record net revenues of $10.2 million, surpassing the $10 million milestone for the first time.
• Delivered the sixth consecutive quarter of double-digit revenue growth (20.9% year-over-year).
• Experienced strong growth across all segments, with Domestic Core revenues up 15.3%, International Core revenues up 33.9%, and Pharma Services and Clinical Trials revenues up 42.1%.
• Increased gross profit by $1.0 million, or 18.2%, compared to the prior year period.
• Achieved positive adjusted EBITDA of $0.3 million, a significant turnaround from a negative adjusted EBITDA of ($0.4) million in the prior year.
• Reduced net loss substantially to $0.2 million from $0.98 million in the prior year period.
• Raised full-year 2025 net revenue guidance, indicating strong confidence in continued growth.
• Reiterated guidance for positive cash flow from operations for the full year 2025.
• Appointed Adam Kalbermatten as Chief Commercial Officer, strengthening the leadership team.
• Expanded the Freedom Infusion System's indication for use with Empaveli, broadening its market applicability.
• Submitted for FDA 510(k) clearance for a new commercialized rare disease biologic drug, signaling future product integration and market expansion.

Negatives

• Gross margin decreased to 63.5% in Q2 2025 from 65.0% in the prior year period, primarily due to a favorable inventory valuation adjustment in the prior year and current year tariff-related charges.
• Cash and cash equivalents decreased by $1.53 million from December 31, 2024, to June 30, 2025, reflecting a quarterly cash usage of $0.6 million.

Risks

• Uncertainties associated with SCIg market growth.
• Risks related to prefilled syringe penetration.
• Dependence on plasma supply.
• Uncertainties regarding clinical trial activity and success.
• Risks associated with the approval and commercialization of new drug indications.
• Challenges related to the shift to increased healthcare delivery in the home.
• Variability in new patient diagnoses.
• Fluctuations in customer ordering patterns.
• Impacts of global health crises.
• Challenges from innovation and competition.
• Risks of labor and supply price increases.
• Impacts of inflationary pressures.
• Availability and cost of labor supply.
• Effects of tariffs on operations and costs.

Future Outlook

KORU Medical Systems raised its full-year 2025 net revenue guidance to $39.5 $40.5 million, representing 18% 20% growth, from the previous range of $38.5 $39.5 million. The company reiterated its full-year gross margin guidance of 61% 63% and expects positive cash flow from operations for the full year 2025, with an ending cash balance greater than $8.1 million. Strategic initiatives include continued outperformance in the strong SCIg market through global share gains, advancing international expansion, and submitting a 510(k) filing to add a new drug to the Freedom Infusion System.

Management Comments

• "We achieved a milestone this quarter, surpassing $10 million in revenue for the first time and delivering our sixth consecutive quarter of double-digit growth."
• "Strategically, we continued to outperform the strong SCIg market through global share gains, advanced our international expansion, and submitted a 510(k) filing to add a new drug to our Freedom Infusion System."
• "Operationally, we delivered positive adjusted EBITDA, reflecting our disciplined execution and focused capital allocation, while continuing to invest in strategic growth areas."
• "We believe this performance positions us well to drive continued shareholder value as we scale."

Industry Context

KORU Medical's strong Q2 2025 performance, including global share gains and outperformance in the subcutaneous immunoglobulin (SCIg) market, indicates a robust position within the medical technology sector. The company's focus on patient-centric large volume subcutaneous infusion solutions aligns with the broader trend towards increased healthcare delivery in the home. The submission for FDA 510(k) clearance for a new commercialized rare disease biologic drug highlights the company's commitment to expanding its product applications and partnerships within the biopharmaceutical industry, leveraging its Freedom Infusion System for specialized drug administration.

Comparison to Industry Standards

• The filing states that KORU Medical continued to outperform the strong SCIg market through global share gains, but it does not provide specific comparable companies, projects, or quantitative benchmarks to assess this performance against industry standards.

Management Changes

Stakeholder Impact

• Shareholders: Positive financial results, raised guidance, and strategic advancements are likely to enhance shareholder value.
• Patients: Expanded indications for the Freedom Infusion System and new drug integrations improve treatment options and quality of life for patients requiring large volume subcutaneous infusions.
• Employees: The appointment of a Chief Commercial Officer and increased temporary headcount for new product development indicate growth and potential for new opportunities.
• Customers (Healthcare Professionals/Accounts): Higher consumable volumes and market share gains suggest increased adoption and satisfaction with KORU Medical's products.
• Biopharmaceutical Companies: Growth in the Pharma Services and Clinical Trials business and the FDA 510(k) submission for a new drug integration indicate strong partnerships and support for drug development.

Next Steps

• Host a live conference call and webcast on August 6, 2025, at 4:30 PM ET to discuss results and provide a corporate update.
• Continue to invest in strategic growth areas.
• Advance international expansion efforts.
• Pursue FDA 510(k) clearance for a commercialized rare disease biologic drug with the Freedom Infusion System.

Key Dates

Recommendation

The company delivered record revenue, achieved positive adjusted EBITDA, and significantly reduced its net loss, demonstrating strong operational execution and financial improvement. The raised full-year revenue guidance, coupled with strategic advancements like the new CCO appointment, expanded drug indications, and an FDA 510(k) submission for a new biologic, indicate robust growth prospects and market expansion. Despite a slight gross margin dip due to specific factors, the overall trajectory is highly positive, suggesting significant upside potential for investors.

Keywords

Medical Technology, Subcutaneous Infusion, Home Healthcare, Drug Delivery, KORU Medical, KRMD, Financial Results, Q2 2025, Revenue Guidance, Adjusted EBITDA, FDA Clearance, Empaveli, Rare Disease Biologic